Drugmakers Get Broader Protection From Generics After Court Says A Means Any
Posted in IP News
Caraco Pharmaceutical Labs and Sun Pharmaceutical Ind. tried to get a rehearing en banc regarding the counterclaim provision of the Hatch-Waxman Act (HWA). Novo Nordisk A/S v. Caraco Pharmaceutical Labs and Sun Pharmaceutical Ind., US Court of Appeals for the Federal Circuit (2010-1001). The petition for panel rehearing and for rehearing en banc was denied. [...]
Related posts:Supreme Court Certiorari: Summary Dispositions of Classen and Prometheus The Supreme Court issued GVR Orders* on two important biotech…
Structurally Similar Drug with Different Biological Properties Meets Criteria for Term Extension After the US Patent and Trademark Office denied a patent…
Drug Label Encouraging Infringing Use Shows Intent to Induce (Even if Prescribed for Noninfringing Use) A featured document in the Docket Report recently highlighted an…
Related posts brought to you by Yet Another Related Posts Plugin.
Comments are closed.
